This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Tamas Racz, MD; Peter G. Sacks, PhD; Dorothy L. Taylor, MS; Stimson P. Schantz, MD

Arch Otolaryngol Head Neck Surg. 1989;115(11):1322-1328.

Abstract
• This study analyzed the capacity of both fresh unseparated peripheral blood lymphocytes and enriched natural killer (NK) cells to lyse head and neck cancer cell lines. In a 6-hour chromium-release assay, only Leu-19⁺ NK cells mediated significant lysis. Furthermore, cell lines established from poorly differentiated cancers were more sensitive to lysis than were cell lines established from well-differentiated cancers. Cell lines from well-differentiated cancers also less readily inhibited K562 lysis in a cold-target inhibition assay, were not recognized by NK cells in a monolayer absorption assay (unlike poorly differentiated cancers), and failed to form conjugates with NK cells in a single-cell assay. These results indicated that deficient killing of a well-differentiated cancer cell vs a poorly differentiated cancer cell is partly a function of diminished NK cell recognition and tumor binding necessary to initiate lysis. As in previous studies regarding the prognostic implication of quantitated measures of NK cell activity within head and neck cancer patients, the results support the biologic relevance of the NK cell as a defense mechanism against metastatic disease, especially in patients with poorly differentiated, low major histocompatibility complex class I–expressing head and neck cancers.

(Arch Otolaryngol Head Neck Surg. 1989;115:1322-1328)

Author Affiliations
From the Department of Head and Neck Surgery, University of Texas M. D. Anderson Cancer Center, Houston.

Footnotes
Accepted for publication August 7, 1989.

Read before the American Society of Head and Neck Surgery, San Francisco, Calif, April 6, 1989.

Reprint requests to Department of Head and Neck Surgery, Box 69, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 (Dr Schantz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Inhibition of Lymphocyte Function by Head and Neck Carcinoma Cell Line Soluble Factors
Bailet et al.
Arch Otolaryngol Head Neck Surg 1997;123:855-862.
ABSTRACT  

Effect of Wound Infections on Head and Neck Cancer
Ramadan and Wetmore
Arch Otolaryngol Head Neck Surg 1992;118:486-487.
ABSTRACT  

Acute-Phase Proteins in Patients With Head and Neck Cancer Treated With Interleukin 2/Interferon Alfa
Clayman et al.
Arch Otolaryngol Head Neck Surg 1992;118:41-48.
ABSTRACT  

The Analysis of Natural Killer Cell Activity by Flow Cytometry
Racz et al.
Arch Otolaryngol Head Neck Surg 1990;116:440-446.
ABSTRACT